Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024544 · ClinicalTrials.gov registry record · Phase 2
Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
A Phase 2 study, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00024544 is a Phase 2 study that has completed, run by Facet Biotech. The registered enrollment target is 120 participants.
The verdict
NCT00024544, a Phase 2 study, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate an investigational medication to treat chronic asthma. The research is being conducted at 20 clinical research sites in the US and is open to both men and women ages 18 to 70 years. Participants in the study will have a number of visits to a research site over an 8-month period. All study-related care and medication is provided to qualified participants at no cost. This includes all visits, examinations and laboratory work.
Interventions
- DRUG anti-IL-4 monoclonal antibody (pascolizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2001-08 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00024544
The ClinicalTrials.gov registry entry for NCT00024544 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anti-IL-4 monoclonal antibody (pascolizumab) is the first listed.
NCT00024544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00024544 about?
NCT00024544 is a clinical study titled "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma". The purpose of the study is to evaluate an investigational medication to treat chronic asthma. The research is being conducted at 20 clinical research sites in the US and is open to both men and women ages 18 to 70 years. Participants in the study will have a number of visits to a research site over...
What is the current status of trial NCT00024544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2001-08. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00024544?
The interventions under investigation include: anti-IL-4 monoclonal antibody (pascolizumab) (DRUG).
Who is sponsoring clinical trial NCT00024544?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.